Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
The Conversation logo

Of the hundreds of potential COVID-19 vaccines in development, six are in the final stages of testing, known as phase 3 clinical trials. One of these – ChAdOx1 nCoV-19 – is the vaccine we’re developing at the University of Oxford.

To be approved, vaccines need to go through multiple rounds of testing to show that they’re safe and effective. A combined phase 1 and phase 2 trial of the Oxford vaccine has demonstrated that it is safe – with only short-term side-effects and no serious unexpected events reported – and that it elicits an immune response.

The purpose of a phase 3 trial is to assess whether this vaccine-induced immune response is strong enough to actually protect people from COVID-19. Proving this would pave the way for the vaccine to become publicly available.

Read the full article on The Conversation website, written by Rebecca Ashfield and (The Jenner Institute)

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

Similar stories

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.

Three NHSBT research units launch at University of Oxford

The NIHR has awarded three new Blood and Transplant Research Units (BTRUs) to the University of Oxford.

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.